Scope and Claim Strength of US Patent 8,546,399 (Drug Substance and Composition Coverage)
US Patent 8,546,399 claims a very large genus of substituted benzamide sulfonamides defined around a shared core scaffold (pyrrolo[2,3-b]pyridine-5-yloxy benzamide bearing a piperazine-linked, cyclohexenyl substituent and a sulfonamide-linked anilide bearing nitro substituents). Claim 1 is a species-enumerating “selected from the group consisting of …” list that, in practice, captures a broad set of marketed or development candidates within that structural class. Dependent claims then narrow to specific stereoisomers, specific substituent options, and two specific named exemplars, plus pharmaceutical composition claims.
Critically, the claim set is structured for (i) coverage of many close analogs within the same chemotype, (ii) forcing any close competitor to either step outside the enumerated species or attack the validity/interpretation of the genus structure, and (iii) capturing at least some embodiments as single-numbered “anchor” compounds useful for enforcement leverage.
What is the core chemical scaffold protected by US Patent 8,546,399?
Short answer: The patent protects substituted benzamide-sulfonamide compounds in which a pyrrolo[2,3-b]pyridine-5-yloxy group is coupled to a benzamide that is further substituted by a piperazine tether and a cyclohexenyl moiety, with a nitro-containing anilide sulfonamide portion whose aryl substituent pattern and heterocycle sidechain are varied across many enumerated species.
What structural elements recur across the claim list (practical reading of Claim 1)
Across the massive list of compounds in Claim 1, the same “building blocks” recur:
-
Heteroaryl ether on the benzamide ring
- “2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide” appears as the benzamide core.
- This creates a fixed pharmacophore element.
-
Piperazine substitution on the benzamide scaffold
- “4-(…piperazin-1-yl)…benzamide” appears repeatedly.
- This indicates the benzamide ring is substituted at a defined position by piperazine nitrogen.
-
A substituted cyclohexenyl (4,4-dimethylcyclohex-1-en-1-yl) element
- The fragment “2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl” is repeatedly attached through a methylene to piperazine.
- This is a strong chemotype anchor for both structure and synthesis.
-
Sulfonamide-linked aniline ring with nitro substitution
- Many enumerated species are of the form “N-(…phenyl)sulfonyl” where the phenyl bears “3-nitro” and additional substituents such as amino sidechains, methoxy linkers, or other groups.
- Nitro substitution (“3-nitro-…”) is a repeated, enabling constraint.
-
Substituent and stereochemistry flexibility
- Claim 1 is exceptionally rich in substituent variation: nitro positions and nitro-containing anilide sulfonyls are fixed in many embodiments, but heterocyclic amine sidechains vary widely (piperidine, morpholine, oxetane, tetrahydro-2H-pyran, tetrahydrofuran, azetidine, spirocyclic variants, etc.).
- Several entries specify stereochemistry: “cis/trans”, “(3R)/(3S)”, “(1S,3R)”-type descriptors, and bicyclic stereochemical patterns.
How Claim 9 expands coverage beyond the enumerated species list
Claim 9 transitions from the enumerated “selected from” format into a Markush-style Formula (III) approach. It defines variable groups with options for:
- A1, A2
- B1 (including NHR1, NHC(O)R1, halogens, etc.)
- D1, E1
- Y1 substituents including “H, CN, NO2, … CF3, R17, OR17, SR17, SO2R17, C(O)NH2”
- Multiple nested variable definitions for R4/R5/R7/R8/R10/R11/R12/R14/R16/R17/R22 etc.
This architecture matters: it can be used to argue the patent covers a broader chemotype family than the enumerated Claim 1 list, depending on how the court construes Formula (III) and how strictly the “selected from” limitations are treated.
What does Claim 1 actually cover: species enumeration vs. true genus?
Short answer: Claim 1 is a species-enumerating claim that recites a long list of specific compounds under “selected from the group consisting of …”. That is legally different from a classical broad Markush genus where any compound meeting a structural formula is within scope. Here, Claim 1’s coverage for many embodiments depends on whether the accused compound matches one of the enumerated structures exactly (or falls within a recognized interpretation of “compound” and salt variants, and how the claim is construed).
Key legal reading for infringement strategy
- If a competitor’s candidate is one of the enumerated compounds, Claim 1 provides direct literal path.
- If the competitor’s candidate is a close analog not present in the list, Claim 1 may not reach it, but Claims 9+ (Formula (III)) may still create coverage, depending on whether the analog satisfies the formula constraints.
What role do salts play?
Claim 1 begins: “A compound, or a pharmaceutically acceptable salt thereof …”. That adds salt coverage for any enumerated species (and potentially for Formula (III) if salts are also encompassed in Claims 9 onward). That matters for competitors who try to commercialize a different counterion.
Which dependent claims narrow coverage by stereochemistry and substituent choice?
Short answer: Dependent claims (2-8, 10-19, 21-24) lock in stereochemistry (cis/trans and R/S configurations), select specific members from Claim 9’s variable set, and secure composition claims for at least two specific anchor compounds and for certain claims defined by Claim number.
Stereochemistry-locked claims
- Claim 2: “Trans-…morpholin-4-ylcyclohexyl…” species
- Claim 3: “Cis-…methylcyclohexyl…” species
- Claim 4: “Trans-…methylcyclohexyl…” species
- Claim 6: “Trans? / Cis? (explicit cis-/trans- labels)” for hydroxy-methylcyclohexyl substituted embodiments
- Claims 7, 10-12, 13, 14, 15: repeatedly select exact stereochemical species, e.g. “(3R)”/“(3S)” substituted tetrahydro-2H-pyran or pyrrolidinyl variants and morpholine variants.
Variable-substitution and Markush constraint selections
- Claim 16: fixes Y1 to “NO2” and constrains other variable definitions (A1, B1, D1, E1).
- Claim 17: fixes Y1 to “SO2R12” and R17 to alkyl.
- Claim 18: constrains R5 to alkyl.
- Claims 19, 22-24: lock in specific anchor members.
Anchor compounds for enforcement leverage
The patent calls out specific members that likely correspond to exemplified compounds in the specification. These appear in dependent claims:
- Claim 14: a specific substituted compound with “4-fluorotetrahydro-2H-pyran-4-yl)methoxy” pattern
- Claim 15: a specific “1-methylpiperidin-4-yl)methyl” substitution
- Claim 22: a specific member with “tetrahydro-2H-pyran-4-ylmethyl” and “3-nitro” anilide sulfonyl
- Claim 21: composition claim featuring the tetrahydro-2H-pyran-4-ylmethyl embodiment
These are useful because they can simplify claim charts in litigation: rather than proving satisfaction of a complicated Markush formula, the patentee can anchor infringement to a single enumerated structure.
How broad are the composition claims in US Patent 8,546,399?
Short answer: Composition coverage exists in parallel with substance coverage, but only for subsets of claims and enumerated compounds. The breadth is constrained by explicit claim numbering in the composition claims.
Composition claim set
- Claim 20: “A pharmaceutical composition comprising an excipient and the compound or pharmaceutically acceptable salt of any one of claims 1, 2-5, 6, 7, 8, 10, 11, 12, 13, 14, and 15-17.”
- This is broad across many enumerated compounds from Claim 1 and many selected dependent claims.
- Claim 21: composition specifically comprising one named anchor compound (the tetrahydro-2H-pyran-4-ylmethyl anilide sulfonyl species) and an excipient.
- Claims 23-24: composition versions for specific claim members, again with excipient as the only required additional element.
Practical effect for generic entry and licensing
Any generic applicant or licensee manufacturing the protected substance and formulating it into a typical dosage form with excipient can still be within the composition claims. Because the claims are generic in dosage form terms (“pharmaceutical composition comprising an excipient”), enforcement can target formulations regardless of pill vs tablet vs capsule, so long as the excipient relationship is satisfied and the substance is within the covered set.
What is the likely “scope map” of Claim 1: what substituent regions can change and still remain inside?
Short answer: Claim 1 keeps several scaffold elements fixed while varying the following regions widely:
- the aniline sulfonamide sidechain (heterocycle, linker, substitution and stereochemistry),
- certain aryl sulfonyl substituents (examples include groups bearing CF3, SO2R, methoxy/methoxyalkyl, hydroxyl-containing rings),
- and multiple linker variations (methoxy, methoxy-methyl, dioxane-derived linkers, oxetane/azetidine insertions).
Fixed versus variable regions (useful for freedom-to-operate screening)
More fixed (repeat in many species):
- pyrrolo[2,3-b]pyridine-5-yloxy
- benzamide orientation “2-(… )benzamide” with piperazine at “4-” position
- piperazine-alkyl linkage to a substituted cyclohexenyl core
- nitro on aniline sulfonyl ring (frequent “3-nitro”)
More variable:
- the substituent at the aniline sulfonamide nitrogen side (R groups like tetrahydropyran/pyrrolidine/morpholine, piperidinyl, oxetanyl/azetidinyl, morpholinylpropyl)
- stereochemistry assignments (cis/trans and R/S)
- the presence/absence of extra functional groups such as hydroxyl, nitrile, additional CF3 or sulfonyl groups
How strong is this patent for deterring close analogs and biosimilar-style “variant” products?
Short answer: Strong against close analogs that are enumerated in Claim 1 or that fall within Formula (III) limitations in Claim 9. It is also strong against attempts to “variant only by salt” because salts are explicitly included. It is less strong against compounds that step outside the Formula (III) constraints and are also not listed in Claim 1.
Key reasons for strength
- Claim 1 enumerates a large cohort of specific compounds.
- Claim 9 adds Markush-style flexibility for additional structures.
- Dependent claims constrain stereochemistry, enabling both broad and narrow enforcement options.
- Composition claims extend protection to formulations containing covered substances.
Key reasons for limits
- Claim 1’s “selected from group consisting of” language can be read as requiring presence within the list, not mere structural similarity.
- Formula coverage depends on strict satisfaction of variable definitions; competitors can avoid by selecting substituents outside the explicit allowed sets.
What is the competitive and litigation relevance of the claim structure?
Because the claim language is heavily chemistry-specific and explicitly enumerated, the patent is likely positioned for structure-based enforcement against identifiable candidates in discovery, preclinical, and clinical development within the same chemotype.
For licensing and defensive strategy:
- Claim 1 can support high-confidence infringement positions for enumerated “target” molecules.
- Claims 9 and 16-18 can support broader arguments for close formula-compliant variants, depending on how courts treat Markush scope.
- Composition claims allow leverage even if the substance is supplied and formulated by a third party.
Key Takeaways
- US 8,546,399 protects a chemotype anchored by pyrrolo[2,3-b]pyridine-5-yloxy benzamide, a piperazine-linked substituted cyclohexenyl unit, and nitro-containing anilide sulfonamide elements.
- Claim 1 is species-enumerating via “selected from the group consisting of” a very large list, with salts included.
- Claim 9 provides Formula (III) Markush-style coverage, expanding beyond enumerated species by variable group definitions and substituent options.
- Dependent claims lock in specific stereochemistry and substituent patterns, including cis/trans and defined R/S configurations.
- Composition claims (Claims 20-24) extend coverage to pharmaceutical formulations containing covered substances plus an excipient, enabling formulation-level enforcement.
FAQs
1. Does US 8,546,399 cover all stereoisomers of the scaffold?
No. Multiple dependent claims specify cis/trans and R/S configurations, meaning coverage is strongest for stereoisomeric embodiments that are explicitly selected in the claim list or satisfy Formula (III) definitions in Claims 9-19.
2. If a compound is not listed in Claim 1, can it still infringe?
Yes, if it meets the Formula (III) requirements under Claim 9 (and dependent claim restrictions), and if the compound falls within the allowed substituent sets and scaffold constraints.
3. Are salt forms protected automatically?
Yes. Claim 1 and other claims include “pharmaceutically acceptable salt thereof,” covering salt variants for covered compounds.
4. Do the composition claims require any particular dosage form?
No. The composition claims require a pharmaceutical composition comprising an excipient plus a covered compound (or its salt), without limiting to tablet, capsule, or injection.
5. What is the fastest enforcement pathway: Claim 1 or Claim 9?
Claim 1 is the fastest for compounds that match an enumerated species exactly. Claim 9 is the faster pathway for structurally compliant analogs that satisfy the Formula (III) variable definitions but are not explicitly listed.
References
- United States Patent No. 8,546,399. “Claims” section (provided claim text).
